Mass General Brigham: Saving Sight
OphthalmologyMass General Brigham: Saving Sight
1.0 AMA PRA Category 1 Credit(s) ™ 1.0 ANCC Contact Hours
March 14, 2024
The accreditation for this activity has expired.
Primary Audience:
Primary care clinicians, endocrinologists, diabetes specialists, internal medicine
Relevant Terms:
| 1. | Explain the risk factors for diabetic retinopathy (DR) and the importance of early screening. | 2. | Describe the benefits of current treatment options for DR, including VEGF inhibitors. |
| 3. | Describe the AAO recommendations for retinal screening of all patients with diabetes. |
| 1. | Explain the risk factors for diabetic retinopathy (DR) and the importance of early screening. |
| 2. | Describe the benefits of current treatment options for DR, including VEGF inhibitors. |
| 3. | Describe the AAO recommendations for retinal screening of all patients with diabetes. |
Jointly provided by Partners for Advancing Clinical Education (PACE) and DKBmed, LLC.
Target Audience
This activity is intended for primary care clinicians and allied health providers who treat patients with type 2 diabetes.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), DKBmed, and the Institute for Johns Hopkins Nursing. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
Acknowledgement
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals.
Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not the specific proprietary business interest of an ineligible company.
| Faculty | Conflicts of Interest |
|---|---|
| David S. Friedman, MD, PhD | Research: Perivision, Inc, Genentech, Inc Consultant, Advisor, Speaker: Life Biosciences, Kalyope, Inc, Abbvie Other (Meeting Funding): Thea Pharmaceuticals |
Planners and Managers
The PACE planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
Launch: March 14, 2024
Expiration: December 31, 2025
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com. For technical issues, please contact info@dkbmed.com
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |
© 2007-2026 HealthCourse, Inc. All rights reserved.
